The case for dosing dabigatran: How tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio

Apostolos Safouris, Nikos Triantafyllou, John Parissis, Georgios Tsivgoulis

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgroup of patients that could be either over-treated, risking bleeding, or under-treated, risking embolism. Additional post-marketing data lends support to the favorable therapeutic profile of dabigatran but at the same time raises doubts about patient characteristics such as weight, age, renal function and their pharmacokinetic effects that, in some cases, could be serious enough to expose a minority of patients to risk. We will present a clinical case of a patient with an ischemic stroke while on dabigatran that was found with low dabigatran plasma levels and we will discuss the currently available data on the effects of inherent patient characteristics on dabigatran pharmacokinetics, the clinical impact of dabigatran plasma levels on safety and efficacy as well as the possibility of improving the risk-benefit profile of this agent by tailoring the dose for selected patient groups.

Original languageEnglish (US)
Pages (from-to)245-254
Number of pages10
JournalTherapeutic Advances in Neurological Disorders
Volume8
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Odds Ratio
Kidney
Weights and Measures
Pharmacokinetics
Drug Monitoring
Dabigatran
Marketing
Embolism
Atrial Fibrillation
Stroke
Clinical Trials
Hemorrhage
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Neurology
  • Clinical Neurology

Cite this

The case for dosing dabigatran : How tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio. / Safouris, Apostolos; Triantafyllou, Nikos; Parissis, John; Tsivgoulis, Georgios.

In: Therapeutic Advances in Neurological Disorders, Vol. 8, No. 6, 01.01.2015, p. 245-254.

Research output: Contribution to journalReview article

@article{7393a66e372e442f953b34c5604d8b3e,
title = "The case for dosing dabigatran: How tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio",
abstract = "Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgroup of patients that could be either over-treated, risking bleeding, or under-treated, risking embolism. Additional post-marketing data lends support to the favorable therapeutic profile of dabigatran but at the same time raises doubts about patient characteristics such as weight, age, renal function and their pharmacokinetic effects that, in some cases, could be serious enough to expose a minority of patients to risk. We will present a clinical case of a patient with an ischemic stroke while on dabigatran that was found with low dabigatran plasma levels and we will discuss the currently available data on the effects of inherent patient characteristics on dabigatran pharmacokinetics, the clinical impact of dabigatran plasma levels on safety and efficacy as well as the possibility of improving the risk-benefit profile of this agent by tailoring the dose for selected patient groups.",
author = "Apostolos Safouris and Nikos Triantafyllou and John Parissis and Georgios Tsivgoulis",
year = "2015",
month = "1",
day = "1",
doi = "10.1177/1756285615601360",
language = "English (US)",
volume = "8",
pages = "245--254",
journal = "Therapeutic Advances in Neurological Disorders",
issn = "1756-2856",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - The case for dosing dabigatran

T2 - How tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio

AU - Safouris, Apostolos

AU - Triantafyllou, Nikos

AU - Parissis, John

AU - Tsivgoulis, Georgios

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgroup of patients that could be either over-treated, risking bleeding, or under-treated, risking embolism. Additional post-marketing data lends support to the favorable therapeutic profile of dabigatran but at the same time raises doubts about patient characteristics such as weight, age, renal function and their pharmacokinetic effects that, in some cases, could be serious enough to expose a minority of patients to risk. We will present a clinical case of a patient with an ischemic stroke while on dabigatran that was found with low dabigatran plasma levels and we will discuss the currently available data on the effects of inherent patient characteristics on dabigatran pharmacokinetics, the clinical impact of dabigatran plasma levels on safety and efficacy as well as the possibility of improving the risk-benefit profile of this agent by tailoring the dose for selected patient groups.

AB - Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgroup of patients that could be either over-treated, risking bleeding, or under-treated, risking embolism. Additional post-marketing data lends support to the favorable therapeutic profile of dabigatran but at the same time raises doubts about patient characteristics such as weight, age, renal function and their pharmacokinetic effects that, in some cases, could be serious enough to expose a minority of patients to risk. We will present a clinical case of a patient with an ischemic stroke while on dabigatran that was found with low dabigatran plasma levels and we will discuss the currently available data on the effects of inherent patient characteristics on dabigatran pharmacokinetics, the clinical impact of dabigatran plasma levels on safety and efficacy as well as the possibility of improving the risk-benefit profile of this agent by tailoring the dose for selected patient groups.

UR - http://www.scopus.com/inward/record.url?scp=84945532654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945532654&partnerID=8YFLogxK

U2 - 10.1177/1756285615601360

DO - 10.1177/1756285615601360

M3 - Review article

AN - SCOPUS:84945532654

VL - 8

SP - 245

EP - 254

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

SN - 1756-2856

IS - 6

ER -